A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects With Hematological Malignancies (waveLINE-001)

  • STATUS
    Not Recruiting
  • End date
    Oct 1, 2023
  • participants needed
    330
  • sponsor
    VelosBio Inc.
Updated on 20 October 2022
renal function
cancer
myeloid leukemia
hematologic malignancy
cyclophosphamide
chronic lymphocytic leukemia
tyrosine
lymphoma
hydroxyurea
acute leukemia
cytarabine
HIV Infection
antiviral
leukemia
bone marrow procedure
lymphocytic leukemia
progressive disease
chemotherapy regimen
follicular lymphoma
cancer chemotherapy
diffuse large b-cell lymphoma
b-cell lymphoma
mantle cell lymphoma
immunoglobulin
marginal zone lymphoma
renal function tests
large b-cell lymphoma
lymphadenopathy
b-cell small lymphocytic lymphoma

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated hematological cancers including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Burkitt lymphoma (BL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Richter transformation lymphoma (RTL), and T-cell non-Hodgkin lymphoma (NHL).

Details
Condition Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, Richter Transformation Lymphoma, Burkitt Lymphoma, Lymphoplasmacytoid Lymphoma, T-cell Non-Hodgkin Lymphoma, Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Waldenstrom Macroglobulinemia
Treatment VLS-101, VLS-101 Schedule 1, VLS-101 Schedule 2, VLS-101 Schedule 3, Zilovertamab vedotin
Clinical Study IdentifierNCT03833180
SponsorVelosBio Inc.
Last Modified on20 October 2022

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note